Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and ...

The composition of sweat makes it a valuable diagnostic fluid. While it is mostly water, the small fraction containing ...

The effects of beta-blocker therapy in post-myocardial infarction (MI) patients with mildly reduced left ventricular ejection fraction (LVEF 40−49%) are largely unknown.  A prespecified, individual ...

Although cardiac glycosides have been used for many years to treat heart failure, randomised trial evidence only exists for digoxin, in a trial conducted more than 25 years ago.   The recent DIGIT-HF ...

Two new trials and a meta-analysis presented at the European Society of Cardiology Congress put the spotlight on the use of beta-blocker therapy after myocardial infarction in patients with preserved ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Article Views are the COUNTER-compliant sum of full text article downloads since ...

The team’s patented process eases assembly of hollow continuous fibre reinforced thermoplastic composite parts. This is precisely where the change of paradigm occurs, making it possible to democratise ...

Few large scale prediction models of clinical outcomes in repaired tetralogy of Fallot (rTOF) exist. Further, contraction fraction, a novel parameter indexing stroke volume by mass reflecting ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

Purpose: Recent evidence suggests that empagliflozin (EMPA) and metformin (MET) may improve prognosis in heart failure with preserved ejection fraction (HFpEF) patients. This study aims to compare ...